Akebia Therapeutics, Inc. (AKBA) Debt by Year
Akebia Therapeutics, Inc. carried $48.3M in long-term debt against $184.8M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 24.7% from the prior fiscal year. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Akebia Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
AKBA Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $48.3M+24.7% | $38.7M+125.2% | $17.2M-49.6% | $34.1M | N/A | $96.4M+27.1% | $75.8M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $184.8M+256.4% | $51.9M+20.8% | $42.9M-52.6% | $90.5M-39.6% | $149.8M-34.5% | $228.7M+55.1% | $147.4M+40.9% | $104.6M+49.2% | $70.2M-62.6% | $187.3M+276.3% | $49.8M+51.9% | $32.8M+54.5% | $21.2M+1192.8% | $1.6M |
AKBA Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $24.8M-47.4% | $36.4M-21.7% | $48.3M+24.7% | $47.6M+24.2% | $47.1M+23.7% | $46.5M+54.3% | $38.7M+125.2% | $38.4M+10.8% | $38.0M+105.7% | $30.1M+14.6% | $17.2M-49.6% | $34.6M-47.5% |
| Cash & Equivalents | $155.5M+13.3% | $162.6M+43.5% | $184.8M+256.4% | $166.4M+389.3% | $137.3M+247.6% | $113.4M+170.2% | $51.9M+20.8% | $34.0M-26.9% | $39.5M-26.3% | $42.0M-26.3% | $42.9M-52.6% | $46.5M-67.9% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Akebia Therapeutics, Inc. financials
Frequently Asked Questions
What was Akebia Therapeutics, Inc.'s long-term debt in fiscal year 2025?
Akebia Therapeutics, Inc. carried $48.3M in long-term debt against $184.8M in cash and equivalents at the end of fiscal year 2025.
How fast is Akebia Therapeutics, Inc.'s long-term debt growing?
Akebia Therapeutics, Inc. (AKBA) long-term debt rose by 24.7% year over year, from $38.7M to $48.3M in fiscal year 2025.
What was Akebia Therapeutics, Inc.'s long-term debt in the most recent quarter?
Akebia Therapeutics, Inc. (AKBA) reported $24.8M in long-term debt in Q2 2026. This represents a decrease of 47.4% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Akebia Therapeutics, Inc. (AKBA) reported on that line in every period on record.